SCHEMBL4240788

SCHEMBL4240788

Cc1cccc(-c2ccccc2C(=O)NCCC(C)C)c1N

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 10/20 0.57
F3 P13726 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 2/20 0.46
MAPK1 P28482 1/20 0.45
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10099558 0.82 HPGD (0.59) KCNA5SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL2204460 0.79 KCNA5 (0.70) KCNA5F3SMN1; SMN2NPC1RAB9A
SCHEMBL11087644 0.79 NPC1 (0.63) KCNA5SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL27647723 0.78 SMN1; SMN2 (0.51) KCNA5SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL4242979 0.77 KCNA5 (0.54) KCNA5SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL7227098 0.76 KCNA5 (0.59) KCNA5F3SMN1; SMN2NPC1RAB9A
SCHEMBL31301322 0.76 MEN1 (0.51) SMN1; SMN2NPC1RAB9AKMT2APOLB
SCHEMBL22573778 0.74 ADORA2A (0.46) KCNA5F3SMN1; SMN2NPC1RAB9A
SCHEMBL15966070 0.74 HPGD (0.64) SMN1; SMN2NPC1RAB9AKMT2AMAPK1
SCHEMBL11087638 0.73 NPC1 (0.60) KCNA5SMN1; SMN2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2004-05-27 US disclosed
US-6686395-B2 THERAPY OF A CARDIAC ARRYTHMIA WHICH CAN BE ELIMINATED BY ACTION POTENTIAL PROLONGATION; POTASSIUM CHANNEL MODULATOR AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-02-03 US disclosed
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6531495-B1 Potassium channel AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, KCNH1 KCNA5 104/4885F3 392/4885SMN1; SMN2 4349/4885
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, CACNA1E KCNA5 97/4885F3 399/4885SMN1; SMN2 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.